Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 10/20 | 0.81 |
| ▸ | AVPR2 | P30518 | 14/20 | 0.68 |
| ▸ | AVPR1A | P37288 | 6/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20727392 | 0.92 | AVPR2 (0.81) | OXTRAVPR2AVPR1AKCNH2 | |
| SCHEMBL20727332 | 0.92 | AVPR2 (0.80) | OXTRAVPR2AVPR1AKCNH2 | |
| SCHEMBL20727340 | 0.91 | AVPR2 (0.79) | OXTRAVPR2AVPR1AKCNH2 | |
| SCHEMBL20727355 | 0.90 | OXTR (1.00) | OXTRAVPR2AVPR1A | |
| SCHEMBL20727404 | 0.90 | OXTR (0.81) | OXTRAVPR2AVPR1AKCNH2 | |
| SCHEMBL20729361 | 0.90 | AVPR2 (0.68) | OXTRAVPR2AVPR1AKCNH2 | |
| SCHEMBL20727605 | 0.89 | AVPR2 (0.69) | OXTRAVPR2AVPR1AKCNH2 | |
| SCHEMBL20727351 | 0.88 | AVPR2 (0.81) | OXTRAVPR2AVPR1AKCNH2 | |
| SCHEMBL20727567 | 0.88 | AVPR2 (0.69) | OXTRAVPR2AVPR1AKCNH2 | |
| SCHEMBL20727402 | 0.88 | AVPR2 (0.67) | OXTRAVPR2AVPR1AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858943-B2 | Vasopressin receptor antagonists and products and methods related thereto | Neumora Therapeutics, Inc. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11186577-B2 | Vasopressin receptor antagonists and products and methods related thereto | BLACKTHORN THERAPEUTICS, INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20190048013-A1 | VASOPRESSIN RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | Neumora Therapeutics, Inc. | 2019-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11186577-B2 | Vasopressin receptor antagonists and products and methods related thereto | AVPR1B, AVPR1A, AVPR2 | OXTR 8/4885AVPR2 3/4885AVPR1A 2/4885 |
| US-20190048013-A1 | VASOPRESSIN RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | AVPR1B, AVPR1A, AVPR2 | OXTR 8/4885AVPR2 3/4885AVPR1A 2/4885 |
| US-11858943-B2 | Vasopressin receptor antagonists and products and methods related thereto | AVPR1B, AVPR1A, AVPR2 | OXTR 8/4885AVPR2 3/4885AVPR1A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.